Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T18:23:13.395Z.
Calculation as of: 2026-10-06T18:23:13.395Z.
Quote observation: 2026-10-06T18:20:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ca1169366ca7231828fa2f87c24c2e776dca628497ffd55dbb7a20e210c1aea1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$1.22B
Price/OCF Ratio
18.85
TTM Avg
22.01
3Y Avg
32.46
5Y Avg
37.26
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | $1.20B | N/A | N/A | N/A | N/A |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.20B | N/A | N/A | N/A | N/A |
| MannKind Corporation (MNKD)vs › | $1.21B | N/A | 46.69 | 49.24 | 49.24 |
| Innovage Holding Corp. (INNV)vs › | $1.22B | 18.85 | 22.01 | 32.46 | 37.26 |
| Cronos Group Inc. (CRON)vs › | $1.22B | 20.36 | 36.33 | 71.26 | 71.26 |
| Omada Health (OMDA)vs › | $1.23B | 51.73 | 51.28 | 51.28 | 51.28 |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.17B | N/A | N/A | N/A | N/A |
| Kardigan, Inc. (KARD)vs › | $1.25B | N/A | N/A | N/A | N/A |
| Nektar Therapeutics (NKTR)vs › | $1.15B | N/A | 9.13 | 9.13 | 9.13 |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.14B | 5.67 | 5.50 | 12.06 | 21.65 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
